Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy
Primary Purpose
Vomiting of Pregnancy
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ondansetron
Sponsored by
About this trial
This is an interventional treatment trial for Vomiting of Pregnancy focused on measuring nausea, vomiting, pregnancy, ondansetron, doxylamine, vitamin B6, pyridoxine
Eligibility Criteria
Inclusion Criteria:
- Women who are less than 16 weeks pregnant by last menstrual period or ultrasound
- Greater than 18 years of age
- English speaking
- No significant visual or hearing impairment
- Requesting treatment for nausea associated with pregnancy
Exclusion Criteria:
- If nausea or vomiting preexisted the pregnancy
- Requires hospitalization at the time of initial enrollment
- Already taking anti-emetics to include metoclopramide, ondansetron, doxylamine, pyridoxine, or promethazine
- The patient has an allergy to either study regimen
- If they are unable to return for a follow up visit in 1 week
Sites / Locations
- Naval Medical Center, San Diego
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Ondansetron
Doxylamine and Pyridoxine (vitamin B6)
Arm Description
study drug
other nausea treatment in use
Outcomes
Primary Outcome Measures
Reduction of nausea on the VAS (Visual Analog Scale)
Secondary Outcome Measures
Reduction in vomiting on the VAS
Any adverse effects caused by the study medications.
Full Information
NCT ID
NCT01668069
First Posted
August 15, 2012
Last Updated
April 4, 2016
Sponsor
United States Naval Medical Center, San Diego
1. Study Identification
Unique Protocol Identification Number
NCT01668069
Brief Title
Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy
Official Title
Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
April 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
United States Naval Medical Center, San Diego
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Our purpose is to determine whether ondansetron, a commonly used antiemetic, is equivalent in efficacy to the combination of pyridoxine and doxylamine, the currently recommended first line therapy for nausea and vomiting in pregnancy by the American Congress of Obstetricians and Gynecologists (ACOG). Since both treatments are safe in pregnancy, many physicians are using ondansetron as first line in practice. Despite this practice and the recommendations from ACOG, there is not data to suggest that ether practice is superior. This will be the first prospective, randomized, double blind, controlled trial comparing the two treatments. We hypothesize that ondansetron will be equally efficacious in reducing nausea and episodes of emesis. By alleviating nausea and vomiting associated with pregnancy, patients will likely benefit from less Emergency Department visits, urgent clinic visits, and admissions for progression to hyperemesis gravidarum.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vomiting of Pregnancy
Keywords
nausea, vomiting, pregnancy, ondansetron, doxylamine, vitamin B6, pyridoxine
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ondansetron
Arm Type
Experimental
Arm Description
study drug
Arm Title
Doxylamine and Pyridoxine (vitamin B6)
Arm Type
No Intervention
Arm Description
other nausea treatment in use
Intervention Type
Drug
Intervention Name(s)
Ondansetron
Other Intervention Name(s)
Zofran
Intervention Description
Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
Primary Outcome Measure Information:
Title
Reduction of nausea on the VAS (Visual Analog Scale)
Time Frame
5 days
Secondary Outcome Measure Information:
Title
Reduction in vomiting on the VAS
Time Frame
5 days
Title
Any adverse effects caused by the study medications.
Time Frame
5 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women who are less than 16 weeks pregnant by last menstrual period or ultrasound
Greater than 18 years of age
English speaking
No significant visual or hearing impairment
Requesting treatment for nausea associated with pregnancy
Exclusion Criteria:
If nausea or vomiting preexisted the pregnancy
Requires hospitalization at the time of initial enrollment
Already taking anti-emetics to include metoclopramide, ondansetron, doxylamine, pyridoxine, or promethazine
The patient has an allergy to either study regimen
If they are unable to return for a follow up visit in 1 week
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lauren G Oliveira, DO
Organizational Affiliation
United States Naval Medical Center, San Diego
Official's Role
Principal Investigator
Facility Information:
Facility Name
Naval Medical Center, San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92134
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25198265
Citation
Oliveira LG, Capp SM, You WB, Riffenburgh RH, Carstairs SD. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. Obstet Gynecol. 2014 Oct;124(4):735-742. doi: 10.1097/AOG.0000000000000479.
Results Reference
derived
Learn more about this trial
Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy
We'll reach out to this number within 24 hrs